Cellmid Ltd
ASX:CDY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (26.3), the stock would be worth AU$-0.54 (1 094% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2.6 | AU$0.05 |
0%
|
| Industry Average | 26.3 | AU$-0.54 |
-1 094%
|
| Country Average | 13.2 | AU$-0.27 |
-600%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Cellmid Ltd
ASX:CDY
|
10.9m AUD | -2.6 | -3.2 | |
| FR |
|
L'Oreal SA
PAR:OR
|
199.5B EUR | 23 | 32.6 | |
| UK |
|
Unilever PLC
LSE:ULVR
|
92.2B GBP | 9.9 | 11.2 | |
| IN |
|
Hindustan Unilever Ltd
NSE:HINDUNILVR
|
5.5T INR | 47.1 | 37.4 | |
| UK |
|
HALEON PLC
LSE:HLN
|
31.2B GBP | 11.8 | 18.7 | |
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
28B USD | 16.7 | -157.1 | |
| DE |
|
Beiersdorf AG
XETRA:BEI
|
15.8B EUR | 20.2 | 16.9 | |
| JP |
|
Kao Corp
TSE:4452
|
2.7T JPY | 13.5 | 22.4 | |
| IN |
|
Godrej Consumer Products Ltd
NSE:GODREJCP
|
1.1T INR | 46.5 | 60.9 | |
| CA |
|
Relevium Technologies Inc
XTSX:RLV
|
12.2B CAD | 552.9 | -4 624.4 | |
| IN |
|
Dabur India Ltd
NSE:DABUR
|
801.7B INR | 42.4 | 43.3 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 8.9 |
| Median | 13.2 |
| 70th Percentile | 19.2 |
| Max | 8 864.3 |
Other Multiples
Cellmid Ltd
Glance View
Cellmid Ltd. operates as a biotechnology company, which engages in the development and marketing of therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-12-09. The firm is specialized in developing anti-aging solutions. The firm operates through two segments: Diagnostics and Consumer Health. The firm is engaged in the research and development of diagnostic and therapeutic products for the management of diseases, such as cancer and various chronic inflammatory conditions by targeting midkine. The company is also engaged in the development and sale of over the counter (OTC) and cosmetic products for hair loss and anti-aging hair care through its FGF5 inhibitor technology. The company has developed a range of products under the evolis, evolis Professional, Lexilis Hybrid, Jo-JuRED and Lexilis BLACK brands.
